Copyright Reports & Markets. All rights reserved.

Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size, Status and Forecast 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Key Market Segments
    • 1.3 Players Covered
    • 1.4 Market Analysis by Type
      • 1.4.1 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size Growth Rate by Type (2014-2025)
      • 1.4.2 Drugs
      • 1.4.3 Devices
    • 1.5 Market by Application
      • 1.5.1 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Share by Application (2014-2025)
      • 1.5.2 Hospitals
      • 1.5.3 Clinics
      • 1.5.4 Others
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Global Growth Trends

    • 2.1 Benign Prostatic Hyperplasia (BPH) Treatment Market Size
    • 2.2 Benign Prostatic Hyperplasia (BPH) Treatment Growth Trends by Regions
      • 2.2.1 Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Regions (2014-2025)
      • 2.2.2 Benign Prostatic Hyperplasia (BPH) Treatment Market Share by Regions (2014-2019)
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers
      • 2.3.3 Market Opportunities

    3 Market Share by Key Players

    • 3.1 Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Manufacturers
      • 3.1.1 Global Benign Prostatic Hyperplasia (BPH) Treatment Revenue by Manufacturers (2014-2019)
      • 3.1.2 Global Benign Prostatic Hyperplasia (BPH) Treatment Revenue Market Share by Manufacturers (2014-2019)
      • 3.1.3 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Concentration Ratio (CR5 and HHI)
    • 3.2 Benign Prostatic Hyperplasia (BPH) Treatment Key Players Head office and Area Served
    • 3.3 Key Players Benign Prostatic Hyperplasia (BPH) Treatment Product/Solution/Service
    • 3.4 Date of Enter into Benign Prostatic Hyperplasia (BPH) Treatment Market
    • 3.5 Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Type and Application

    • 4.1 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Type (2014-2019)
    • 4.2 Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Application (2014-2019)

    5 United States

    • 5.1 United States Benign Prostatic Hyperplasia (BPH) Treatment Market Size (2014-2019)
    • 5.2 Benign Prostatic Hyperplasia (BPH) Treatment Key Players in United States
    • 5.3 United States Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Type
    • 5.4 United States Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Application

    6 Europe

    • 6.1 Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Size (2014-2019)
    • 6.2 Benign Prostatic Hyperplasia (BPH) Treatment Key Players in Europe
    • 6.3 Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Type
    • 6.4 Europe Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Application

    7 China

    • 7.1 China Benign Prostatic Hyperplasia (BPH) Treatment Market Size (2014-2019)
    • 7.2 Benign Prostatic Hyperplasia (BPH) Treatment Key Players in China
    • 7.3 China Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Type
    • 7.4 China Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Application

    8 Japan

    • 8.1 Japan Benign Prostatic Hyperplasia (BPH) Treatment Market Size (2014-2019)
    • 8.2 Benign Prostatic Hyperplasia (BPH) Treatment Key Players in Japan
    • 8.3 Japan Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Type
    • 8.4 Japan Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Application

    9 Southeast Asia

    • 9.1 Southeast Asia Benign Prostatic Hyperplasia (BPH) Treatment Market Size (2014-2019)
    • 9.2 Benign Prostatic Hyperplasia (BPH) Treatment Key Players in Southeast Asia
    • 9.3 Southeast Asia Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Type
    • 9.4 Southeast Asia Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Application

    10 India

    • 10.1 India Benign Prostatic Hyperplasia (BPH) Treatment Market Size (2014-2019)
    • 10.2 Benign Prostatic Hyperplasia (BPH) Treatment Key Players in India
    • 10.3 India Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Type
    • 10.4 India Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Application

    11 Central & South America

    • 11.1 Central & South America Benign Prostatic Hyperplasia (BPH) Treatment Market Size (2014-2019)
    • 11.2 Benign Prostatic Hyperplasia (BPH) Treatment Key Players in Central & South America
    • 11.3 Central & South America Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Type
    • 11.4 Central & South America Benign Prostatic Hyperplasia (BPH) Treatment Market Size by Application

    12 International Players Profiles

    • 12.1 Pfizer
      • 12.1.1 Pfizer Company Details
      • 12.1.2 Company Description and Business Overview
      • 12.1.3 Benign Prostatic Hyperplasia (BPH) Treatment Introduction
      • 12.1.4 Pfizer Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2014-2019)
      • 12.1.5 Pfizer Recent Development
    • 12.2 Sanofi
      • 12.2.1 Sanofi Company Details
      • 12.2.2 Company Description and Business Overview
      • 12.2.3 Benign Prostatic Hyperplasia (BPH) Treatment Introduction
      • 12.2.4 Sanofi Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2014-2019)
      • 12.2.5 Sanofi Recent Development
    • 12.3 GlaxoSmithKline
      • 12.3.1 GlaxoSmithKline Company Details
      • 12.3.2 Company Description and Business Overview
      • 12.3.3 Benign Prostatic Hyperplasia (BPH) Treatment Introduction
      • 12.3.4 GlaxoSmithKline Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2014-2019)
      • 12.3.5 GlaxoSmithKline Recent Development
    • 12.4 Boston Scientific
      • 12.4.1 Boston Scientific Company Details
      • 12.4.2 Company Description and Business Overview
      • 12.4.3 Benign Prostatic Hyperplasia (BPH) Treatment Introduction
      • 12.4.4 Boston Scientific Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2014-2019)
      • 12.4.5 Boston Scientific Recent Development
    • 12.5 Teleflex
      • 12.5.1 Teleflex Company Details
      • 12.5.2 Company Description and Business Overview
      • 12.5.3 Benign Prostatic Hyperplasia (BPH) Treatment Introduction
      • 12.5.4 Teleflex Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2014-2019)
      • 12.5.5 Teleflex Recent Development
    • 12.6 Cardinal Health
      • 12.6.1 Cardinal Health Company Details
      • 12.6.2 Company Description and Business Overview
      • 12.6.3 Benign Prostatic Hyperplasia (BPH) Treatment Introduction
      • 12.6.4 Cardinal Health Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2014-2019)
      • 12.6.5 Cardinal Health Recent Development
    • 12.7 Allergan
      • 12.7.1 Allergan Company Details
      • 12.7.2 Company Description and Business Overview
      • 12.7.3 Benign Prostatic Hyperplasia (BPH) Treatment Introduction
      • 12.7.4 Allergan Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2014-2019)
      • 12.7.5 Allergan Recent Development
    • 12.8 Teva Pharmaceutical
      • 12.8.1 Teva Pharmaceutical Company Details
      • 12.8.2 Company Description and Business Overview
      • 12.8.3 Benign Prostatic Hyperplasia (BPH) Treatment Introduction
      • 12.8.4 Teva Pharmaceutical Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2014-2019)
      • 12.8.5 Teva Pharmaceutical Recent Development
    • 12.9 Mylan
      • 12.9.1 Mylan Company Details
      • 12.9.2 Company Description and Business Overview
      • 12.9.3 Benign Prostatic Hyperplasia (BPH) Treatment Introduction
      • 12.9.4 Mylan Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2014-2019)
      • 12.9.5 Mylan Recent Development
    • 12.10 Eli Lilly
      • 12.10.1 Eli Lilly Company Details
      • 12.10.2 Company Description and Business Overview
      • 12.10.3 Benign Prostatic Hyperplasia (BPH) Treatment Introduction
      • 12.10.4 Eli Lilly Revenue in Benign Prostatic Hyperplasia (BPH) Treatment Business (2014-2019)
      • 12.10.5 Eli Lilly Recent Development

    13 Market Forecast 2019-2025

    • 13.1 Market Size Forecast by Regions
    • 13.2 United States
    • 13.3 Europe
    • 13.4 China
    • 13.5 Japan
    • 13.6 Southeast Asia
    • 13.7 India
    • 13.8 Central & South America
    • 13.9 Market Size Forecast by Product (2019-2025)
    • 13.10 Market Size Forecast by Application (2019-2025)

    14 Analyst's Viewpoints/Conclusions

      15 Appendix

      • 15.1 Research Methodology
        • 15.1.1 Methodology/Research Approach
          • 15.1.1.1 Research Programs/Design
          • 15.1.1.2 Market Size Estimation
          • 12.1.1.3 Market Breakdown and Data Triangulation
        • 15.1.2 Data Source
          • 15.1.2.1 Secondary Sources
          • 15.1.2.2 Primary Sources
      • 15.2 Disclaimer

      Benign prostatic hyperplasia (BPH), also called prostate enlargement, is a noncancerous increase in size of the prostate. Symptoms may include frequent urination, trouble starting to urinate, weak stream, inability to urinate, or loss of bladder control. Complications can include urinary tract infections, bladder stones, and chronic kidney problems.
      In 2018, the global Benign Prostatic Hyperplasia (BPH) Treatment market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

      This report focuses on the global Benign Prostatic Hyperplasia (BPH) Treatment status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Benign Prostatic Hyperplasia (BPH) Treatment development in United States, Europe and China.

      The key players covered in this study
      Pfizer
      Sanofi
      GlaxoSmithKline
      Boston Scientific
      Teleflex
      Cardinal Health
      Allergan
      Teva Pharmaceutical
      Mylan
      Eli Lilly

      Market segment by Type, the product can be split into
      Drugs
      Devices

      Market segment by Application, split into
      Hospitals
      Clinics
      Others

      Market segment by Regions/Countries, this report covers
      United States
      Europe
      China
      Japan
      Southeast Asia
      India
      Central & South America

      The study objectives of this report are:
      To analyze global Benign Prostatic Hyperplasia (BPH) Treatment status, future forecast, growth opportunity, key market and key players.
      To present the Benign Prostatic Hyperplasia (BPH) Treatment development in United States, Europe and China.
      To strategically profile the key players and comprehensively analyze their development plan and strategies.
      To define, describe and forecast the market by product type, market and key regions.

      In this study, the years considered to estimate the market size of Benign Prostatic Hyperplasia (BPH) Treatment are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025
      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now